TABLE 3.

Clinical predictors of detectable anti-SARS-CoV-2 IgG antibodies in liver transplant patients 6 months after COVID-19 (n = 71)

Variables	Univariate analysis		Multivariate analysis
	OR (95% CI)	p	OR (95% CI)	p
Age	1.06 (1.00–1.10)	.026	1.01 (0.94–1.08)	.873
Sex (female)	3.46 (0.89–13.47)	.073	13.49 (2.17–83.80)	.005
Interval since liver transplantation	1.17 (1.06–1.28)	.002	1.19 (1.03–1.37)	.018
Diabetes Mellitus	0.78 (0.29–2.06)	.613
Hypertension	2.21 (0.82–5.99)	.117
ACE inhibitors or ARB	9.58 (2.51–36.57)	.001	7.11 (1.47–34.51)	.015
Cardiovascular disease	0.54 (0.12–2.36)	.410
Severe COVID–19	1.85 (0.34–9.90)	.474
Hospital admission	0.60 (0.15–2.51)	.487
Lopinavir	3.03 (0.89–10.36)	.076	2.33 (0.46–11.76)	.365
Hydroxychloroquine	0.67 (0.12–3.71)	.643
Azithromycin	1.55 (0.58–4.15)	.380
Tocilizumab	0.86 (0.13–5.50)	.871
Corticosteroids (boluses)	1.79 (0.18–18.11)	.624
Tacrolimusa	0.25 (0.08–0.78)	.017	0.37 (0.08–1.67)	.193
Cyclosporinea	1.79 (0.18–18.11)	.624
Mycophenolatea	0.96 (0.36–2.51)	.928
Corticosteroids (maintenance)a	0.30 (0.07–1.38)	.122
Everolimusa	2.79 (0.71–11.00)	.143
Month 6 tacrolimus	1.02 (0.53–1.99)	.947
Month 6 trough concentrations (tacrolimus)	0.79 (0.59–1.07)	.131
Month 6 mycophenolate	1.18 (0.67–2.10)	.568
Month 6 corticosteroids	0.96 (0.57–1.64)	.888
Month 6 everolimus	1.27 (0.72–2.24)	.415

Bold values indicate the variables independently associated with antibody persistence at 6 months in the multivariate analysis.

^aThese variables pertain to active immunosuppression therapy at COVID-19 diagnosis.